http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11535608-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6d218b55eb03086f05afb0ce53155338 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2020-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b69a4ce6c935c223cedaaa32deb5cbe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_761745e02a77070346b84ee90384d59c |
| publicationDate | 2022-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-11535608-B2 |
| titleOfInvention | Prodigiosin analogs and methods of use |
| abstract | Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others. |
| priorityDate | 2016-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 936.